| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Terminated | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer NCT01254734 | City of Hope Medical Center | N/A |
| Completed | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757 | Fox Chase Cancer Center | Phase 2 |
| Terminated | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radi NCT01164566 | Wake Forest University Health Sciences | N/A |
| Completed | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609 | University of Washington | N/A |
| Completed | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck NCT01044433 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Terminated | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receivin NCT01682031 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Cau NCT00895245 | University of Washington | Phase 2 |
| Completed | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194 | Fox Chase Cancer Center | Phase 1 |
| Terminated | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00387335 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or NCT00410826 | University of Washington | Phase 2 |
| Completed | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell NCT00103259 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck NCT00084682 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00095628 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00098631 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00055913 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head NCT00033449 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |